NuVision Biotherapies Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$6.5M
- Investors
-
9
NuVision Biotherapies General Information
Description
Developer of ophthalmic therapy products designed to offer ophthalmic surgeons innovative new therapies for ocular care. The company's therapy harnesses the regenerative properties of amniotic tissue to improve recovery from front-of-the-eye disease, surgical and other traumatic injuries, enabling patients to get quality and affordable biotherapies for treating the front-of-the-eye disease and trauma.
Contact Information
Website
www.nu-vision.co.ukCorporate Office
- MediCity, D6 Building
- Thane Road
- Nottingham NG90 6BH
- England, United Kingdom
Corporate Office
- MediCity, D6 Building
- Thane Road
- Nottingham NG90 6BH
- England, United Kingdom
NuVision Biotherapies Timeline
NuVision Biotherapies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Later Stage VC | 05-Feb-2026 | $6.5M | Completed | Generating Revenue | ||
| 12. Later Stage VC | 01-Aug-2024 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series A) | Cancelled | Generating Revenue | ||||
| 10. Later Stage VC | 01-Apr-2021 | Completed | Generating Revenue | |||
| 9. Grant | 01-Jun-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 02-Apr-2020 | Completed | Generating Revenue | |||
| 7. Grant | Completed | Generating Revenue | ||||
| 6. Grant | 01-Mar-2018 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 05-Jan-2018 | $1.05M | $1.92M | Completed | Generating Revenue | |
| 4. Early Stage VC | 20-Sep-2016 | $330K | $871K | Completed | Startup |
NuVision Biotherapies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| E Ordinary | ||||||||
| E Ordinary | ||||||||
| D Ordinary | ||||||||
| D Ordinary | ||||||||
| D Ordinary | ||||||||
| D Ordinary | ||||||||
| D Ordinary | 1,246 | $0.001385 | $111.17 | $111.17 | 1x | $111.17 | 1.63% | |
| D Ordinary | 2,292 | $0.001385 | $90.05 | $90.05 | 1x | $90.05 | 3% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
NuVision Biotherapies Comparisons
Industry
Financing
Details
NuVision Biotherapies Competitors (2)
One of NuVision Biotherapies’s 2 competitors is PulseSight Therapeutics, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| PulseSight Therapeutics | Venture Capital-Backed | Paris, France | ||||
| Tissue Bank of France | Corporation | Lyon, France |
NuVision Biotherapies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NuVision Biotherapies Patents
NuVision Biotherapies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4680293-A1 | Amniotic membrane and uses thereof | Pending | 15-Mar-2023 | ||
| GB-202303809-D0 | Amniotic membrane and uses thereof | Inactive | 15-Mar-2023 | ||
| WO-2024189380-A1 | Amniotic membrane and uses thereof | Inactive | 15-Mar-2023 | A61L27/3604 |
NuVision Biotherapies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NuVision Biotherapies Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Maven Cognition | Venture Capital | Minority | ||
| Newable Partnership | Growth/Expansion | Minority | ||
| Midlands Engine Investments | Venture Capital | Minority | ||
| Pioneer Group | Venture Capital | Minority | ||
| University of Nottingham Endowment | Limited Partner | Minority |
NuVision Biotherapies FAQs
-
When was NuVision Biotherapies founded?
NuVision Biotherapies was founded in 2015.
-
Where is NuVision Biotherapies headquartered?
NuVision Biotherapies is headquartered in Nottingham, United Kingdom.
-
What is the size of NuVision Biotherapies?
NuVision Biotherapies has 24 total employees.
-
What industry is NuVision Biotherapies in?
NuVision Biotherapies’s primary industry is Therapeutic Devices.
-
Is NuVision Biotherapies a private or public company?
NuVision Biotherapies is a Private company.
-
What is the current valuation of NuVision Biotherapies?
The current valuation of NuVision Biotherapies is .
-
What is NuVision Biotherapies’s current revenue?
The current revenue for NuVision Biotherapies is .
-
How much funding has NuVision Biotherapies raised over time?
NuVision Biotherapies has raised $13.4M.
-
Who are NuVision Biotherapies’s investors?
Maven Cognition, Newable Partnership, Midlands Engine Investments, Pioneer Group, and University of Nottingham Endowment are 5 of 9 investors who have invested in NuVision Biotherapies.
-
Who are NuVision Biotherapies’s competitors?
PulseSight Therapeutics and Tissue Bank of France are competitors of NuVision Biotherapies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
